author-photo

Kirstine Brown Frandsen

Novo Nordisk

18

Papers

4841

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

SELECT (Semaglutide effects on cardiovascular outcomes in people with overweight or obesity) rationale and design

2020 American Heart Journal
Show All
- Source
- Cite
- Save
Citations (29)
Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)

2019 Diabetes, Obesity and Metabolism
Show All
- Source
- Cite
- Save
Citations (8)
DEVOTE 3: Temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality

2018 Diabetologia
Show All
- Source
- Cite
- Save
Citations (86)
Rates of Major Adverse Cardiovascular (CV) Events (MACE) and Mortality with Basal Insulin by Liraglutide Use—A DEVOTE Subanalysis

2018 Diabetes
Show All
- Source
- Cite
- Save
Citations (0)
Rates of Major Adverse Cardiovascular Events and Mortality with Basal Insulin by Liraglutide Use: A DEVOTE Subanalysis

2018 Canadian Journal of Diabetes
Show All
- Source
- Cite
- Save
Citations (0)
Liraglutide and Renal Outcomes in Type 2 Diabetes

2017 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (553)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

2016 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (3492)
Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) – DEVOTE 1

2016 American Heart Journal
Show All
- Source
- Cite
- Save
Citations (48)
Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial

2013 American Heart Journal
Show All
- Source
- Cite
- Save
Citations (172)
Insulin analogues and weight gain

2006
- Kirstine Brown Frandsen
Show All
- Source
- Cite
- Save
Citations (0)